<< Back to Corporate Member News

FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer

FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma

Tecentriq combination improved overall survival and progression-free survival compared to the previous standard of care

Application approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot program

South San Francisco, CA -- May 29, 2020 --

Genentech Press Release Imbrave